Some archive (>10 years old) programs are not reachable through the search engine. They can be found at www.radio4all.net/files/pub Your support is essential if the service is to continue, there are bandwidth bills to pay every month and failing disk drives to replace. Volunteers do the work, but disk drives and bandwidth are not free. Click on this bar to contribute, even a dollar helps.
 
Program Information
 Long Term Memory Radio - CKUT Radio McGill 
 A 10-part "Long-Term Memory Radio" series featuring interviews with health policy analysts, researchers, medical professionals and consumers' rights advocates.
 Documentary
 
 ckut community news  
 For non-profit use only.
See notes below for contents of segments ...
Producer: judith news@ckut.ca
Uploaded by: ckut community news collective news@ckut.ca
Segment 1:

Notes:

What is the pharmaceutical industry's bottom line?
Does the pharmaceutical industry have a social responsibility?
What makes the drug industry unique?

What's all the fuss about intellectual property rights? in the Third World? in Canada?

Hear statements from Peter Lurie of Public Citizen Research Group and Ethel Mead of Ontario Coalition of Senior Citizens' Organizations.

Keywords:

WTO, FTAA, pharmaceutical industry, Canadian industrial policy, intellectual property rights, Third World access to HIV/AIDS medication, clinical trials, US trade sanctions, drug patents, patent protection.


Segment 2

Notes:

How did Canada get rid of its regulatory agencies and open the way for corporate-sponsored university medical research? What well-known Canadians make up the corporate cast of characters?

Genomics: the wave of the future. Has anyone asked why?
What is the nature of the relationship between drug companies and universities?

Keywords:
Canada biotechnology policy, neo-liberalism, private sector research funding, university research, patent legislation, technology transfer, genomics, proteomics, knowledge-based economy, intellectual property, pharmaceutical industry.

Segment 3

Notes:

"The socialization of losses and privatization of profits" and the well-publicized case of a doctor/researcher who wanted to protect her patients from risks associated with a new drug.

How does a drug company justify giving salt water to sick babies instead of medicine? Peter Lurie reports: "To no one's surprise, the babies died." Did this happen in Canada? the U.S.? Guess again.

Plus a statement by Stephen Lewis, UN Special Envoy for HIV/AIDS in Africa, on the impact of HIV/AIDS on African women and girls.

Keywords:

Clinical trials, Canada & Latin America, Dr. Nancy Olivieri, research integrity, thalassemia, "Diferiprone," Apotex, University of Toronto,

Surfactant medication, Third World clinical trials, AZT studies in Africa, Helsinki Declaration, Public Citizen Research Group, the Meningitis Belt.

Segment 4

Notes:

Media reporters need to ask a crucial question when reporting on new media breakthroughs: Who funds your research?

A question for consumers: Are you aware whether or not you are taking an RDNA drug?

keywords:

"Checkbook science," "junk science," medical reporting, breakthrough drugs, "throwaway journals," breast implants, hormone replacement therapy, "Fen-Phen,"

Biotech drugs, drug safety, consumer advocacy, RDNA technology, patent protection, auto-immune diseases, PharmaWatch, Polaris Institute.


Segment 5:


Keywords:

Consumer advocacy, adverse drug reactions, drug interactions, post-market surveillance, disease management, clinical trials, product monographs, synthetic insulin, access to drug information, public health policy, privatization.

Risk/benefit analysis, direct-to-consumer advertising, Celebrex, Vioxx, cholesterol-lowering drugs, osteoporosis drugs, health risks, "prescription culture."

Notes:
Colleen Fuller: "'Disease management' is designed to keep the drug industry's hands in your pockets for as long as they can manage it and for as much as they can take."

Alan Cassels: "How about taking your cholesterol-lowering drug for a five-mile walk?

Segment 6

Notes:

Barbara Mintzes explains how the death of a Canadian teenager from a high-risk new drug is related to direct-to-consumer advertising.

Ellen Reynolds describes health effects on "DES daughters" and "DES sons." She also discusses environmental estrogen and the ongoing "extra-label" use of DES as a veterinary drug in food-producing animals.

Keywords:

Direct-to-consumer advertising, media promotion, "reminder ads," pharmaceutical marketing, doctors' prescription practices, "me-too" drugs, access to information.

Di-ethyl stilbestrol, synthetic hormones, endocrine disruption, environmental estrogen, "DES daughters," "DES sons," DES health effects, medicinal residues, Alliance for Access to Medical Information.


Segment 7

Notes:

Listen for David Healy's answer to these questions:

"Am I being naive in assuming that medical journals are the last bastion of scientific truth in medical reporting?"

"If drug industry marketing of anti-anxiety drugs intensifies after events such as 9/11, does that mean something is wrong with us or with the world?"

Keywords: anti-depressants, serotonin, anxiolytics, Prozac, Zooloft, psychopharmacology, medicalization of neuroses, history of depression, marketing of depression/anxiety, University of Toronto, suicide.

Segment 8:

Notes:

What issues matter most to Canadian consumers where prescription drugs are concerned?

Keywords:

Romanow Commission report, health insurance, health care, consumer advocacy, prescription drugs, medication insurance, senior citizens, Canada Health Act, public drug plan, automatic injunctions, patent protection, pharmaceutical industry.

Segment 9:

Notes:

Does the Canadian government protect citizens from profit-driven drug multinationals?

___ Yes. ___ No. ___ I don't know.

Wendy Armstrong says, "No" and explains why not.

Are there any advantages to a national pharmacare plan?

___ Yes. ___ No. ___ I don't know.

Gordon Guyatt says, "Yes" and explains why.

Keywords: consumer advocacy, drug safety, regulatory regime, drug approval, Health Canada, access to information, drug pricing,
Romanow & Kirby reports, national pharmacare, medication insurance, Consumers' Association of Canada, Medical Reform Group.


Segment 10

Notes:

What is "health freedom" and how does it relate to pharmaceuticals? Why was kava-kava banned in Canada?
Why is the pharmaceutical industry interested in natural remedies and supplements?
What dangers are present in vaccines?
What role do Health Canada and the World Health Organization play in the multinational drug industry's bid to gain control of herbal medicines?
What is the Codex Commission?

Croft Woodruff lays it down for us.

Keywords:

Codex Commission, vitamins & supplements, alternative medicines/therapies, Matthias Rath, Hugh Fudenberg, Zoltan Rona, vaccines, consumer advocacy, Health Canada, World Health Organization.

  Download Program Podcast
09:29:19 English
 
  View Script
    
Part 1: Free Market Drug Profits  00:56:42  64Kbps mp3
(25.83MB) Mono
292 Download File...
Part 2: Drugs, Universities and Government  00:56:01  64Kbps mp3
(25.64MB) Mono
264 Download File...
Part 3: Research Integrity and Human Rights  00:57:33  64Kbps mp3
(26.24MB) Mono
257 Download File...
Part 4: Media Hype and Health Risks  00:55:24  64Kbps mp3
(25.29MB) Mono
256 Download File...
Part 5: Post-Market Surveillance and Drug Safety  00:58:40  64Kbps mp3
(26.73MB) Mono
255 Download File...
Part 6: Drug Advertising and Synthetic Hormones  00:56:05  64Kbps mp3
(25.66MB) Mono
315 Download File...
Part 7: Depression - Marketing and Myth  00:54:39  64Kbps mp3
(24.90MB) Mono
251 Download File...
Part 8: Grassroots Consumer Advocacy  00:57:31  64Kbps mp3
(26.23MB) Mono
246 Download File...
Part 9: Nation-wide Advocacy and a Pharmacare Solution  01:00:00  64Kbps mp3
(27.47MB) Mono
241 Download File...
10  Part 10: Codex Alimentarius - Big Pharma's Next Play  00:56:44  64Kbps mp3
(25.84MB) Mono
266 Download File...